Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on December 13, 2005, covering events that occurred on December 7, 2005. The filing addresses corporate governance changes, specifically the departure of a director and principal officers, and the entry into a material definitive agreement regarding stock option vesting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel matters rather than financial performance.
Material Changes
- Director Resignation: John E. Berriman resigned from the Board of Directors effective December 7, 2005.
- Officer Resignation: Barry E. Greene resigned as Treasurer effective January 1, 2006, but will continue serving as Chief Operating Officer.
- Officer Appointment: Patricia L. Allen, currently Vice President of Finance, was appointed Treasurer effective January 1, 2006. She will serve as the principal financial and accounting officer.
- Board Election: Vicki L. Sato, Ph.D., was elected to the Board to fill the vacancy left by Mr. Berriman. She will serve as a Class II director until the 2006 annual meeting and was appointed to the Nominating and Corporate Governance Committee.
- Committee Appointment: James L. Vincent was appointed to the Compensation Committee.
- Stock Option Acceleration: The Board accelerated the full vesting of an option for 10,000 shares of common stock granted to the resigning director, John E. Berriman, on June 8, 2005.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items. The document is limited to reporting the specific personnel and agreement events listed above.
Investor Verification Checklist
- Verify the effective dates of the Treasurer transition (January 1, 2006) and the impact on financial reporting responsibilities.
- Confirm the background and qualifications of the new director, Dr. Vicki L. Sato, and her role on the Nominating and Corporate Governance Committee.
- Review the terms of the accelerated stock option vesting for John E. Berriman to understand any potential dilution or compensation implications.
- Monitor future filings for the formal appointment of a new Treasurer if Patricia L. Allen's appointment is not finalized as scheduled.